Olio Labs AI Drug Development Funding

Olio Labs is pioneering a novel approach to drug development by leveraging continuous behavioral monitoring in preclinical studies. The biotech startup, founded by systems neuroscientists David Tingley and Tom Roseberry, aims to bridge the critical gap between promising animal trial results and unpredictable human clinical outcomes. By capturing nuanced, real-time physiological and behavioral data from laboratory animals, Olio's artificial intelligence platform seeks to identify subtle indicators of drug efficacy and toxicity that traditional, intermittent assessments often miss.

This innovative methodology addresses a significant challenge in pharmaceutical research: the high failure rate of drug candidates that perform well in animal models but falter in human trials. Conventional studies typically rely on a limited set of predefined measurements taken at specific time points. Olio's system, however, employs advanced computer vision and sensor technology to record every movement, breath, and interaction, creating a rich dataset that can be correlated with actual human clinical results. This allows for the prediction of outcomes like nausea, gastrointestinal distress, and neurotoxicity with greater precision.

The company recently secured $4.5 million in a funding round led by Boom Capital Ventures and Overwater Ventures. This investment also saw participation from notable venture capital firms including Pioneer Fund, SciFounders, Scrum Ventures, Y Combinator, and ZAKA Ventures. This capital infusion will fuel the expansion of Olio's data collection capabilities, with projections to amass over five million hours of mouse data by mid-2027, further refining its predictive AI models.

Olio's journey began with an algorithm designed to discover drug combinations that enhance effectiveness while minimizing adverse effects. Initial experiments with obesity drug candidates, guided by their algorithm, showed promising results, with many combinations outperforming semaglutide in terms of weight loss and reduced nausea. However, the high cost and time required for traditional outsourced assays, coupled with instances where internal testing revealed severe adverse effects missed by external observers, underscored the need for Olio's proprietary continuous monitoring system, the Phenotyping Acquisition Device (PAD).

The strategic importance of Olio's work is amplified by evolving regulatory landscapes. The FDA Modernization Act 2.0 and subsequent initiatives signal a shift away from mandatory animal testing, encouraging the adoption of New Approach Methodologies (NAMs) like cell-based assays and computational models. While Olio's platform still involves animal studies, its focus on generating highly predictive, human-relevant data positions it as a valuable tool during this transitional period, offering a more sophisticated alternative to traditional methods and potentially accelerating the development of safer, more effective therapeutics.

With a foundation built on systems neuroscience expertise, including backgrounds from institutions and companies like NYU, Harvard, and Neuralink, Olio Labs is uniquely positioned to interpret complex biological signals. Their approach differs from other AI-driven biotech firms like Blank Bio or Recursion, which often focus on molecular sequences or cellular imaging. Olio's organism-level, AI-powered drug-response model offers a distinct value proposition by directly addressing the translational challenges in drug development.